SEC Company Response from MARINUS PHARMACEUTICALS, INC. (MRNS) (CIK 0001267813) — May 13, 2020
MARINUS PHARMACEUTICALS, INC. (MRNS) (CIK 0001267813)
Date: May 13, 2020 · CIK: 0001267813 · Accession: 0001104659-20-060846
AI Filing Summary & Sentiment
File numbers found in text: 333-237903
Letter
Marinus Pharmaceuticals, Inc.
5 Radnor Corporate Center, Suite 500
100 Matsonford Rd Radnor, PA 19087
May 13, 2020
VIA EDGAR
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549
Attn: Irene Paik and Joseph McCann
Re: Marinus Pharmaceuticals, Inc.
Registration Statement on Form S-3 (File No. 333-237903)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Marinus Pharmaceuticals, Inc. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3, as amended (the “Registration Statement”), and declare the Registration Statement effective as of 5:00 p.m., Eastern Daylight Time, on May 14, 2020, or as soon thereafter as possible.
Please feel free to direct any questions or comments concerning this request to Steve Abrams of Hogan Lovells US LLP at (267) 675-4671.
Very truly yours,
Marinus Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm Marinus Pharmaceuticals, Inc. 5 Radnor Corporate Center, Suite 500 100 Matsonford Rd Radnor, PA 19087 May 13, 2020 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Attn: Irene Paik and Joseph McCann Re: Marinus Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-237903) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Marinus Pharmaceuticals, Inc. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3, as amended (the “Registration Statement”), and declare the Registration Statement effective as of 5:00 p.m., Eastern Daylight Time, on May 14, 2020, or as soon thereafter as possible. Please feel free to direct any questions or comments concerning this request to Steve Abrams of Hogan Lovells US LLP at (267) 675-4671. Very truly yours, Marinus Pharmaceuticals, Inc. /s/ Edward F. Smith By: Edward F. Smith Title: Vice President, Chief Financial Officer, Secretary and Treasurer [Signature page to acceleration request]